Alder Biopharmaceuticals
Bothell
About Alder Biopharmaceuticals
Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $916.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Apr 2019)
- Ticker: nasdaq:ALDR
- Website: alderbio.com
- Phone: 425-205-2900
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/alder-biopharmaceuticals-178646 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.